Bergen, Norway, 4 October 2021 - Reference is made to the stock exchange notice
published by BerGenBio ASA (the "Company") (OSE: BGBIO) on 30 September 2021
where the Company announced that the board of directors of the Company had
resolved to increase the Company's share capital in connection with the exercise
of options pursuant to the Company's share option program. A total of 137,500
options were exercised and 137,500 new shares were issued at an average
subscription price of NOK 16.01 per share.

The share capital increase has been duly registered in the Norwegian Register of
Business Enterprises. Following such registration, the Company's share capital
is NOK 8,838,525.50 divided into 88,385,255 shares, each with a nominal value of
NOK 0.10.

-End-

Contacts

Rune Skeie

CFO, BerGenBio ASA

Rune.skeie@bergenbio.com

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.